Your SlideShare is downloading. ×
Transfer of novel academic research in vaccines into marketable products – a new business model
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Transfer of novel academic research in vaccines into marketable products – a new business model

480
views

Published on

Transfer of novel academic research in vaccines into marketable products – a new business model …

Transfer of novel academic research in vaccines into marketable products – a new business model

By - Dr. Albrecht Läufer, CEO


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
480
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
19
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Corvay at BioAsia2009 „ Transfer of novel academic research in vaccines into marketable products – a new business model “ Dr. Albrecht Läufer, CEO
  • 2. Corvay at BioAsia2009 Corvay´s Core Competences
    • Corvay is a consulting firm specialized on Life Sciences, founded 2002, based in Hannover, Germany.
    • > 20 years international experience in pharmaceuticals and biotechnology in industry and academia !
    • Proven expertise in business strategy development AND implementation !
    • Excellent network of researchers, associations, industry partners, external experts, government bodies both in Europe and in Asia !
  • 3. Corvay at BioAsia2009 Corvay manages BioRegioN
    • Life Science Network of the State of Niedersachsen…
    • … .. and is coordinating the initiative „Life Science Niedersachsen goes India“ under the umbrella of the research marketing campaign of the German Federal Ministry of Education and Research.
  • 4. Vaccines - Global Needs, Global Markets Highly unmet medical needs: The BIG Three: HIV, Tuberculosis, Malaria. Diarrhea causing diseases. Hepatitis C. Cytomegalovirus. Dengue. Influenza. Cancer. Other diseases related to infections or immune system disorder. Corvay at BioAsia2009
  • 5. Vaccines - Global Needs, Global Markets 21 bn USD global vaccine sales in 2008 (18.5 bn USD in 2007). Prevnar® 3bn USD; Gardasil 2.8 bn USD. Several others >1 bn. “ Classical” mainly pediatric market 6 – 7 bn USD, stable. New vaccines providing the growth. India: 1800 crores = approx 360 mill USD. Russia, Brazil, China, all South East Asia to become big markets. Corvay at BioAsia2009
  • 6. Vaccines - Global Needs, Global Markets Another urgent need : In order to grow further , industry needs new, successful candidates. Corvay at BioAsia2009
  • 7. Corvay at BioAsia2009 Where do new vaccine concepts come from ?
    • academia
    • HPV vaccine invented by 2008 nobel laureate Prof. zur Hausen, DKFZ, German Cancer Research Center.
    • Diphteria serum treatment (1901) by Emil von Behring at Marburg university, later funded by Hoechst.
    • - Many others.
    • Industry, in earlier times national serum institutes.
  • 8. Corvay at BioAsia2009 Situation in German academia 1995 - 2000
    • Prospering science scene with >200 research projects in > 50 scientific groups.
    • Productive collaboration between science and industry, mainly Behringwerke, sold to Chiron in 1996.
    • Working group in the Federal Ministry of Education and Research on how to foster commercialization if academic vaccine research.
    Emil von Behring, 1917
  • 9. Corvay at BioAsia2009 Bridging the gap between academia and industry
    • Main hurdle: mentality / incentive systems.
    • TLO´s (technology licence offices).
      • licence oriented - several university based TLO´s.
      • Licence and Spin out oriented – Max Planck Innovation, Ascenion.
    • Successfull Spin outs: Immatics, CureVac.
    • Project management company.
    • New concepts since 2008: Lead Discovery Center, Screening port.
    • Science Parks, associated to universities and research centers.
  • 10. Corvay at BioAsia2009 Project Management Company
      • key principle: partner ! focus on key expertise of each partner.
      • research / innovation at academic institute (university, Max Planck
      • Institute, Fraunhofer Institute) -> creative and cost effective.
      • process development and manufacturing at appropriate CMO,
      • custom manufacturing organization -> no CapEx !
      • preclinical trial at appropriate CRO.
      • clinical trial with appropriate CRO in appropriate endemic area.
      • all support services (regulatory, patent/IP, quality, legal, HR,
      • accounting) with expert partners.
      • product/indication specific advice from selected experts.
      • plan and manage project „with the final objective in mind“.
  • 11. Corvay at BioAsia2009 Vakzine Projekt Management GmbH
      • founded 2002, operative 2003, 5 later 8 FTE´s, based in Hannover.
      • projects
        • tuberculosis – recombinant live BCG vaccine.
        • prostate cancer – recombinant LNCap cell line.
        • novel interferon-beta Soluferon®, for Multiple Sclerosis.
        • on the shelf: HCMV dense bodies and Malaria MSP-1.
      • management team: CEO, CSO, CFO + 1 project manager per project.
  • 12. Corvay at BioAsia2009 Partners in the Tb vaccine project
  • 13. Corvay at BioAsia2009 Key process steps
      • identify candidate -> German vaccine database.
      • negotiate good licence contract -> back loaded, close
      • communication, scientific collaboration.
      • identify + contract appropriate manufacturing partner (CMO).
      • transfer product technology to CMO partner „hands on“.
      • validate product technology, and key preclinical proof of concept
      • experiment, mechanism of action.
      • develop GMP process, produce preclinical material, phase I
      • material.
      • regular communication with regulatory authority.
      • perform state of the art preclinical and phase I clinical trials,
      • possibly phase II.
      • partner with or licence to industry.
  • 14. Corvay at BioAsia2009 Summary
      • academic research is a major source for innovation in vaccines.
      • a project management company can efficiently bridge the gap to
      • industry.
      • it will not be necessary to establish a new start up company for
        • each new project, the same core management team can be applied while the partner network will be adjusted according to the requirements of the project.
      • a public / private FIPNO...
  • 15. Corvay at BioAsia2009 Thank you very much Corvay GmbH Sofienstr. 6 D - 30159 Hannover phone: +49 511 44 98 95 31 fax: +49 511 44 98 95 99 [email_address] www.corvay.de

×